My Doctor, Lawyer, and Wife Agree...

Why new marijuana legislation will change the industry forever,,, You are receiving this email because you subscribed to Outsider Club. [Click here]( to manage your e-mail preferences. [Outsider Club logo] My Doctor, Lawyer, and Wife Agree... [Jimmy Mengel Photo] By [Jimmy Mengel]( Written Apr. 04, 2019 The two most frightening words in Washington are 'bipartisan consensus.' Bipartisan consensus is when my doctor and my lawyer agree with my wife that I need help. — P.J. O’Rourke As funny as Mr. O’Rourke is, I think that — when it comes to cannabis law — he couldn’t be more wrong. Bipartisan consensus is going to drive the next round of pot profits, and the first shots have already been fired. If I had to rewrite his aphorism, it would read: The two most beautiful words in marijuana investing are 'bipartisan consensus'. It’s when my bankers, brokers and my legal business can actually work together to make everyone money! At long last, the government seems to agree on one thing: marijuana shouldn’t be federally illegal. If it is successful with its most recent bill, we could be off to the races. It could be the beginning of the biggest pot stock boom in history... [Marijuana Has Gone Mainstream]( Cannabis is on its way to becoming a $200 billion industry... It’s disrupting beer and tobacco... it’s transforming medicine and agriculture... And that’s why Coca-Cola, Heineken, Molson, and dozens of the world’s largest mainstream companies are buying up all the cannabis stocks they can find. Famous investors like Warren Buffett, Peter Thiel, and Bill Gates are all piling in, too. I’ve done my boots-on-the-ground research... I have a list of five cannabis stocks that are prime targets for these billions... [you could easily make 1,000% or more if you get in now.]( The big cannabis news rushing out of Washington, D.C. last week was about one of the biggest challenges cannabis companies face: banking. In years past, many banks wouldn’t touch cannabis with a 10-foot pole. That may finally be about to change. The House Financial Services Committee approved landmark legislation aimed at helping banks and other financial institutions count marijuana businesses as clients. The bill would shield banks from federal regulatory penalties if they serve marijuana businesses that are legalized at the state level. The bill was sponsored by Reps. Ed Perlmutter (D-Colo.) and Denny Heck (D-Wash.), but with a nice bipartisan touch as Rep. Steve Stivers (R-Ohio) included an amendment that would extend the same treatment to insurers. Now it must pass through the Senate. That is step one. The next one will be the legislation to end the federal prohibition of cannabis. That could come sooner than we think… [Tiny Company Owns Most Valuable “Pot Patent” In History]( In September 1928, Alexander Fleming discovered Penicillin. It was the world’s first effective antibiotic, and it revolutionized medicine. He’s credited with saving over 200 million lives. And, I’m telling you now — the “Molecule of the Century” is a much bigger deal. It makes medical marijuana up to 80x more effective. It can tackle health markets worth up to $297 billion. Now one $84 million stock owns the most valuable “pot patents” in the world. [Get the facts on the “Molecule of the Century” now.]( House Rules Committee Chairman James McGovern (D-MA) gave a telling interview Wednesday, where he predicted this vote’s passage and went even further, saying “in a relatively short time, within the next several weeks, and I think we will have a very strong vote.” “We will guide it to the House floor for a vote — which I think it will pass with an overwhelming vote — Democrats and I think a lot of Republicans as well.” The House Rules Committee decides how legislation is handled on the floor and holds a lot of sway. These are major developments in an industry that — despite widespread legalization, support, and undeniable financial implications for the American economy — has continued to operate in the shadows. Most companies have had to operate in cash — which is not only dangerous, but costly, as companies have had to hire armed security to courier thousands in cash on a daily basis. It simply doesn't make any sense. I think the time has finally come for the government to step away from a lucrative and legal business. This legislation would legitimize the entire industry and lead to millions in institutional investing, and it will be huge for the pot companies that operate in the United States. [Here’s How the Market Sell-Off Will Begin…]( When funds and ETFs begin to get a surge of sell orders they have to sell some of their holdings. With many stocks selling for hundreds of dollars apiece, the large blocks that ETFs hold splashing into the market’s pool will place severe pressure on stock prices. Automatic buying from robo-investors will then be swamped by a torrent of selling, producing sudden downside gaps. It’s one thing for fund buyers to buy stocks unhurriedly during quietly rising markets, day after day, but quite another for a fund to try and unload a large block of stocks. This is a serious warning: funds and ETFs don’t do well if they don’t have time to unload their positions. Once the main plunge begins, mass fear and contagion will drive others to sell, and that’s where a severe stock market plunge could begin… There’s only one way to save your portfolio — [click here to learn more.]( [I recently spent time with Republican Rep. Dana Rohrabacher]( from California. He failed six times to pass his pro-cannabis bill before succeeding with the famous Rohrabacher–Farr amendment that passed in 2014. It has protected medical cannabis companies from being raided by the federal government ever since. It was the very first time that the House or the Senate voted to protect medical cannabis patients. But it was only the first shot fired in the battle to legalize cannabis countrywide. Many other shots will be fired this year, and I believe 2019 will be the year that the war is officially over. The bills being put forth by Congress this year are very bipartisan. While our politicians cannot seem to agree on anything else, it looks like marijuana may be the one issue that they can cross the aisle on… Who would have guessed? Next up is the CARERS Act, sponsored by Steve Cohen (D-Tenn.) and Don Young (R-Alaska), which would expand marijuana research and give VA doctors the power to recommend cannabis treatment for veterans. The bill would require the federal government to allow states to legalize and regulate their own medical marijuana markets. More importantly, it would allow the U.S. Department of Veterans Affairs to issue medical marijuana recommendations for its patients, which it hasn’t been able to do in the past. The second big bill to hit Congress this year is the “Regulate Marijuana like Alcohol Act.” The bill would remove cannabis from the federal Controlled Substances Act, which would remove the single-biggest hurdle that cannabis faces today. Right now, marijuana is still federally illegal. Cannabis is categorized as a Schedule I substance, which means that it has “high abuse potential, no medical use, and severe safety concerns.” That means that marijuana is lumped in with dangerous drugs like heroin, LSD, and cocaine. Once that stigma goes away, we'll start seeing the true renaissance of pot stocks. All of these initiatives will legitimize the industry, which means institutional money can begin flowing into the investment space. It means that [ETFs will start cropping up](. It means that new companies will be able to grow without the threat of being shut down by the Feds. I suggest you position yourself long before these bills are passed. [Here are five companies you can prepare with...]( Godspeed, [Jimmy Mengel] Jimmy Mengel [follow basic]( [@mengeled on Twitter]( Jimmy is a managing editor for [Outsider Club]( and the investment director of the personal finance advisory, [The Crow's Nest,](and cannabis stocks advisory, [The Marijuana Manifesto.]( For more on Jimmy, check out his editor's [page](. *Follow Outsider Club on [Facebook]( and [Twitter](. This $1 Stock Is Set to Skyrocket The Food and Drug Administration (FDA) recently approved an anti-addiction drug so good that doctors are calling it "a game-changer." Once the big-ticket contracts come in, the share price of the drug's maker will undoubtedly double or even triple. This $1 stock could easily go to $52 a share within the next 12 months. Get in on this now by [clicking here](! Enjoy reading this article? [Click here]( to like it and receive similar articles to read! Browse Our Archives [Introducing Your Own Personal Weed ETF]( [Bill Gates: “I can't overstate how important this is.”]( [This Is What Will Trigger The Next Gold Bull Market]( [Donald Trump’s Useful Idiot]( [Your Local Pharmacy Just Loaded Up On This Drug...]( --------------------------------------------------------------- This email was sent to {EMAIL}. It is not our intention to send email to anyone who doesn't want it. If you're not sure why you've received this e-letter, or no longer wish to receive it, you may [unsubscribe here](, and view our privacy policy and information on how to manage your subscription. To ensure that you receive future issues of Outsider Club, please add to your address book or whitelist within your spam settings. For customer service questions or issues, please contact us for assistance. [Outsider Club](, Copyright © 2019, [Angel Publishing LLC]( & Outsider Club LLC, 111 Market Place #720, Baltimore, MD 21202. For Customer Service, please call (877) 303-4529. All rights reserved. [View our privacy policy here.]( No statement or expression of opinion, or any other matter herein, directly or indirectly, is an offer or the solicitation of an offer to buy or sell the securities or financial instruments mentioned. Angel Publishing and Outsider Club does not provide individual investment counseling, act as an investment advisor, or individually advocate the purchase or sale of any security or investment. Subscribers should not view this publication as offering personalized legal or investment counseling. Investments recommended in this publication should be made only after consulting with your investment advisor and only after reviewing the prospectus or financial statements of the company in question. This letter is not intended to meet your specific individual investment needs and it is not tailored to your personal financial situation. Nothing contained herein constitutes, is intended, or deemed to be – either implied or otherwise – investment advice. Neither the publisher nor the editors are registered investment advisors. This letter reflects the personal views and opinions of Nick Hodge and that is all it purports to be. While the information herein is believed to be accurate and reliable it is not guaranteed or implied to be so. Neither Nick Hodge, nor anyone else, accepts any responsibility, or assumes any liability, whatsoever, for any direct, indirect or consequential loss arising from the use of the information in this letter. The information contained herein is subject to change without notice, may become outdated and may not be updated. Nick Hodge, entities that he controls, family, friends, employees, associates, and others may have positions in securities mentioned, or discussed, in this letter. No part of this letter/article may be reproduced, copied, emailed, faxed, or distributed (in any form) without the express written permission of Nick Hodge or the Outsider Club. Unauthorized reproduction of this newsletter or its contents by Xerography, facsimile, or any other means is illegal and punishable by law.